Clinical, demographic, and immunohistologic features of vancomycin- induced linear IgA bullous disease of the skin: Report of 2 cases and review of the literature

Hossein C. Nousari, Arash Kimyai-Asadi, Juan P. Caeiro, Grant James Anhalt

Research output: Contribution to journalArticle

Abstract

Administration of intravenous vancomycin has been associated with the development of linear IgA bullous disease (LABD). In contrast to the idiopathic variant, vancomycin-induced LABD (VILABD) appears to be more transient and to be associated with lower morbidity. The characteristics of this entity remain undefined. Our analysis of clinical, demographic, and immunopathologic features of 2 new and 14 previously reported patients with VILABD reveals that VILABD is clinically and immunopathologically indistinguishable from its idiopathic variant. A variety of premorbid conditions and concomitant medications were observed, none of which was consistently associated with the development of VILABD. VILABD occurs independently of vancomycin trough levels, resolves promptly upon discontinuation of vancomycin, and recurs more severely and with shorter onset latency with vancomycin rechallenge. This entity should be recognized as 1 of the adverse cutaneous effects of intravenous vancomycin, and warrants prompt diagnosis through direct immunofluorescence skin examination.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalMedicine
Volume78
Issue number1
DOIs
StatePublished - Jan 1999

Fingerprint

Vesiculobullous Skin Diseases
Vancomycin
Immunoglobulin A
Demography
Direct Fluorescent Antibody Technique
Skin
Intravenous Administration

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical, demographic, and immunohistologic features of vancomycin- induced linear IgA bullous disease of the skin : Report of 2 cases and review of the literature. / Nousari, Hossein C.; Kimyai-Asadi, Arash; Caeiro, Juan P.; Anhalt, Grant James.

In: Medicine, Vol. 78, No. 1, 01.1999, p. 1-8.

Research output: Contribution to journalArticle

@article{d537ce6c73704a1382d2d5bea0afdbb4,
title = "Clinical, demographic, and immunohistologic features of vancomycin- induced linear IgA bullous disease of the skin: Report of 2 cases and review of the literature",
abstract = "Administration of intravenous vancomycin has been associated with the development of linear IgA bullous disease (LABD). In contrast to the idiopathic variant, vancomycin-induced LABD (VILABD) appears to be more transient and to be associated with lower morbidity. The characteristics of this entity remain undefined. Our analysis of clinical, demographic, and immunopathologic features of 2 new and 14 previously reported patients with VILABD reveals that VILABD is clinically and immunopathologically indistinguishable from its idiopathic variant. A variety of premorbid conditions and concomitant medications were observed, none of which was consistently associated with the development of VILABD. VILABD occurs independently of vancomycin trough levels, resolves promptly upon discontinuation of vancomycin, and recurs more severely and with shorter onset latency with vancomycin rechallenge. This entity should be recognized as 1 of the adverse cutaneous effects of intravenous vancomycin, and warrants prompt diagnosis through direct immunofluorescence skin examination.",
author = "Nousari, {Hossein C.} and Arash Kimyai-Asadi and Caeiro, {Juan P.} and Anhalt, {Grant James}",
year = "1999",
month = "1",
doi = "10.1097/00005792-199901000-00001",
language = "English (US)",
volume = "78",
pages = "1--8",
journal = "Medicine",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Clinical, demographic, and immunohistologic features of vancomycin- induced linear IgA bullous disease of the skin

T2 - Report of 2 cases and review of the literature

AU - Nousari, Hossein C.

AU - Kimyai-Asadi, Arash

AU - Caeiro, Juan P.

AU - Anhalt, Grant James

PY - 1999/1

Y1 - 1999/1

N2 - Administration of intravenous vancomycin has been associated with the development of linear IgA bullous disease (LABD). In contrast to the idiopathic variant, vancomycin-induced LABD (VILABD) appears to be more transient and to be associated with lower morbidity. The characteristics of this entity remain undefined. Our analysis of clinical, demographic, and immunopathologic features of 2 new and 14 previously reported patients with VILABD reveals that VILABD is clinically and immunopathologically indistinguishable from its idiopathic variant. A variety of premorbid conditions and concomitant medications were observed, none of which was consistently associated with the development of VILABD. VILABD occurs independently of vancomycin trough levels, resolves promptly upon discontinuation of vancomycin, and recurs more severely and with shorter onset latency with vancomycin rechallenge. This entity should be recognized as 1 of the adverse cutaneous effects of intravenous vancomycin, and warrants prompt diagnosis through direct immunofluorescence skin examination.

AB - Administration of intravenous vancomycin has been associated with the development of linear IgA bullous disease (LABD). In contrast to the idiopathic variant, vancomycin-induced LABD (VILABD) appears to be more transient and to be associated with lower morbidity. The characteristics of this entity remain undefined. Our analysis of clinical, demographic, and immunopathologic features of 2 new and 14 previously reported patients with VILABD reveals that VILABD is clinically and immunopathologically indistinguishable from its idiopathic variant. A variety of premorbid conditions and concomitant medications were observed, none of which was consistently associated with the development of VILABD. VILABD occurs independently of vancomycin trough levels, resolves promptly upon discontinuation of vancomycin, and recurs more severely and with shorter onset latency with vancomycin rechallenge. This entity should be recognized as 1 of the adverse cutaneous effects of intravenous vancomycin, and warrants prompt diagnosis through direct immunofluorescence skin examination.

UR - http://www.scopus.com/inward/record.url?scp=0032934286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032934286&partnerID=8YFLogxK

U2 - 10.1097/00005792-199901000-00001

DO - 10.1097/00005792-199901000-00001

M3 - Article

C2 - 9990350

AN - SCOPUS:0032934286

VL - 78

SP - 1

EP - 8

JO - Medicine

JF - Medicine

SN - 0025-7974

IS - 1

ER -